Jump to content

AGU and Genedata Partner to Offer Integrated Bioprocess Automation Solution

The collaboration enables direct integration of AGU’s Sm@rtline Data Cockpit with the Genedata Biopharma Platform to automate and streamline process development workflows in GxP validated environments

June 3, 2024
Basel, Switzerland

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that they are entering into a strategic partnership with AGU, a leading provider of middleware integrating a wide range of devices in GxP validated and non-validated environments. The collaboration provides a fully integrated, comprehensive laboratory digitalization solution to automate data capture from instruments and streamline data flow into the Genedata enterprise platform.

“AGU's expertise in integrating laboratory equipment is vital to help our biopharma customers to accelerate their digital transformation,” said Othmar Pfannes, Ph.D., CEO of Genedata. “With the Genedata Biopharma Platform, we focus on automating the full range of bioprocess development workflows while simultaneously maintaining an open and collaborative approach with other technology providers in the domain. This partnership will allow our joint customers to further simplify and automate instrument data capture while maintaining full data integrity, which will result in additional efficiency gains.”

“We have advanced Sm@rtline Data Cockpit®️ (SDC) into a widely adopted solution by developing device-specific drivers to automate the transfer of data from all major instrument manufacturers,” said Klaus Bruch, CTO and Co-Founder of AGU. “Importantly, we ensure GxP compliance for all our instrument integrations. This guarantees full data integrity according to highest standards. Using robust drivers, SDC extracts data ranging from simple instruments such as pH meters to more complicated instruments such as cell counters and metabolite analyzers.”
Used together, Genedata and AGU offer a comprehensive solution that delivers data from devices in highest quality, based on ISO 27001 and ISO 9001 standards, and also supports data consumers — including laboratory personnel, operators, process engineers, and data sciences groups. Having a fully integrated solution that automates instrument data capture and is maintained and supported out-of-the-box is a huge advantage for IT groups.

Since both Genedata and AGU work with the top-25 pharmaceutical companies globally, the companies’ shared customer base will benefit from the newly offered integrated platform, which will deliver substantial time and cost savings.

About AGU

AGU was founded in 1992 and is based in Leverkusen (Germany). Our software solutions are marketed worldwide, and we develop our products exclusively "Made in Germany". Today, AGU employs more than 90 people in the areas of industrial IT and process automation. Both areas especially complement each other which led to the development of SDC the Sm@rtLine Data Cockpit®️, which is used today by the 25 largest pharmaceutical companies in the world.

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube


Allison Kurz
Public Relations


The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

This partnership will allow our joint customers to further simplify and automate instrument data capture while maintaining full data integrity, which will result in additional efficiency gains.


Othmar Pfannes, Ph.D.
CEO at Genedata